BioPharma Resources

Drug Trial Radar · NCT05433506

Safety and Pharmacokinetics of HU6

A Phase 1, Two-Part Study to Assess the Safety and Pharmacokinetics of Tablet and Capsule Formulations of HU6 in Obese Subjects.

Last checked: Nov 19, 2026Latest source record: Mar 20, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

30

Actual

Start

Sep 15, 2022

Primary completion

Jan 30, 2023

Study completion Mar 15, 2023

Sponsor

Lead sponsor
Rivus Pharmaceuticals, Inc.Industry
Sponsor type
Industry
First posted
Jun 27, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Crossover
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 55 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

Part 1 is an open-label, randomized, Latin-square 2x2 crossover study. Twelve subjects will be randomized (1:1) to treatment sequence to determine the order in which they will receive the tablet or capsule formulation in Period 1 and Period 2. Part 2 is an open-label study of up to 4 single, ascending dose levels of HU6 administered as the tablet formulation. Eight subjects will be enrolled to participate in all of the ascending study periods.

Conditions

  • Obese

Interventions

  • HU6 TabletDrug

    Six subjects will receive a tablet formulation.

  • HU6 CapsuleDrug

    Six subjects will receive the capsule formulation

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Assess the dose relationship of PK Parameter CmaxTime frame: 150 days

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Nucleus Network

    Minneapolis, Minnesota

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.